ZVRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Zevra Therapeutics Inc (ZVRA) is not a strong buy at the moment for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. While the company has a promising analyst rating and a significant revenue increase in the latest quarter, the stock's technical indicators, insider selling trends, and negative short-term price trend suggest caution. Additionally, the lack of recent positive news or AI trading signals further supports a hold recommendation.
The MACD is positive and expanding, indicating a bullish momentum. However, RSI is neutral at 68.947, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 8.757, with resistance at 9.116 and support at 8.398. Overall, the technical indicators do not strongly favor a buy at this time.
Analyst H.C. Wainwright maintains a Buy rating with a $26 price target, citing the expanded access program for Miplyffa as a growth opportunity.
Revenue increased by 605.36% YoY in Q3 2025, indicating strong top-line growth.
Insiders are selling heavily, with an 809.12% increase in selling activity over the last month.
The stock is projected to decline by -4.21% in the next day, -5.63% in the next week, and -13.95% in the next month based on historical candlestick patterns.
Net income, EPS, and gross margin have all significantly declined YoY, raising concerns about profitability.
In Q3 2025, revenue increased by 605.36% YoY to $26.06M, but net income dropped by -98.36% YoY to -$544K. EPS fell by -98.55% YoY to -$0.01, and gross margin declined by -2371.50% YoY to 94.04. While revenue growth is impressive, profitability metrics have deteriorated significantly.
H.C. Wainwright reiterates a Buy rating with a $26 price target, highlighting the expanded access program for Miplyffa as a growth driver. The analyst believes this opportunity is not yet priced into the stock.
